The DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
Etiology of Ibrutinib Therapy Discontinuation and Outcomes in Patients With Chronic Lymphocytic Leukemia
Open accessAbstract
IMPORTANCE: The Bruton tyrosine kinase (BTK) inhibitor ibrutinib is effective in patients with chronic lymphocytic leukemia (CLL). Reasons for discontinuing therapy with this drug and outcomes following discontinuation have not been evaluated outside of clinical trials with relatively short follow-up. OBJECTIVE: To determine features associated with discontinuation of ibrutinib therapy and outcomes. DESIGN, SETTING, AND PARTICIPANTS: A total of 308 patients participating in 4 sequential trials of ibrutinib at The Ohio State University Comprehensive Cancer Center were included. These clinical trials accrued patients included in this analysis from May 2010 until April 2014, and data were locked in June 2014. MAIN OUTCOMES AND MEASURES: Patients were evaluated for time to therapy discontinuation, reasons for discontinuation, and survival following discontinuation. For patients who discontinued therapy because of disease progression, targeted deep sequencing was performed in samples at baseline and time of relapse. RESULTS: With a median follow-up of 20 months, 232 patients remained on therapy, 31 had discontinued because of disease progression, and 45 had discontinued for other reasons. Disease progression includes Richter's transformation (RT) or progressive CLL. Richter's transformation appeared to occur early and CLL progressions later (cumulative incidence at 12 months, 4.5% [95% CI, 2.0%-7.0%] and 0.3% [95% CI, 0%-1.0%], respectively). Median survival following RT was 3.5 months (95% CI, 0.3-6.0 months) and 17.6 months (95% CI, 4.7 months-"not reached") following CLL progression. Sequencing on peripheral blood from 8 patients with RT revealed 2 with mutations in BTK, and a lymph node sample showed no mutations in BTK or PLCG2. Deep sequencing on 11 patients with CLL progression revealed BTK or PLCG2 mutations in all. These mutations were not identified before treatment in any patient. CONCLUSIONS AND RELEVANCE: This single-institution experience with ibrutinib confirms it to be an effective therapy and identifies, for the first time, baseline factors associated with ibrutinib therapy discontinuation. Outcomes data show poor prognosis after discontinuation, especially for those patients with RT. Finally, sequencing data confirm initial reports associating mutations in BTK and PLCG2 with progression and clearly show that CLL progressions are associated with these mutations, while RT is likely not. TRIAL REGISTRATIONS: clinicaltrials.gov Identifiers:NCT01105247, NCT01217749, NCT01589302, and NCT01578707.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In published studies of disease progression during BTKi therapy,approximately 35% of patients were found to have aBTK mutation alone, an additional 10% had a coexisting mutations in PLCG2, 5% of cases had a PLCG2mutation alone, and the remaining 50% were wild-type (WT) for BTK and PLCG2 (Figure 2)(12, 19, 21–31).”
From Resistance Mechanisms and Approach to Chronic Lymphocytic Leukemia after BTK Inhibitor Therapy (2025) · cites this paper as [27]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Interestingly, two separate studies observed that there were no PLCγ2 or BTK mutations detected in patients with CLL before Ibrutinib treatment (127, 128).”
From The role of PLCγ2 in immunological disorders, cancer, and neurodegeneration (2021) · cites this paper as [128]
In the citing paper
“While the most common ibrutinib-resistant BTK mutant is C481S, other mutants observed in patients include C481R, C481F, C481Y, T474I, and T474S.33”
From Bruton tyrosine kinase degradation as a therapeutic strategy for cancer (2019) · cites this paper as [33]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A Proportional Hazards Model for the Subdistribution of a Competing Risk
Fine, J. P., & Gray, R. J. (1999) · Journal of the American Statistical Association · doi:10.1080/01621459.1999.10474144 · Cited by 14,290
A Class of $K$-Sample Tests for Comparing the Cumulative Incidence of a Competing Risk
Gray, R. J. (1988) · The Annals of Statistics · doi:10.1214/aos/1176350951 · Cited by 4,957
Clinical staging of chronic lymphocytic leukemia
Rai, K., Sawitsky, A., Ep, C., Chanana, A. D., Levy, R., & Pasternack, B. (1975) · Blood · doi:10.1182/blood.v46.2.219.219 · Cited by 2,789
Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia
Byrd, J. C., Furman, R. R., Coutre, S. E., Flinn, I. W., Burger, J. A., Blum, K. A., Grant, B., Sharman, J. P., Coleman, M., Wierda, W. G., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1215637 · Cited by 2,270
Self-citationIdelalisib and Rituximab in Relapsed Chronic Lymphocytic Leukemia
Furman, R. R., Sharman, J. P., Coutre, S. E., Cheson, B. D., Pagel, J. M., Hillmen, P., Barrientos, J. C., Zelenetz, A. D., Kipps, T. J., Flinn, I. W., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1315226 · Cited by 1,725
Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid Leukemia
Byrd, J. C., Brown, J. R., O'Brien, S. M., Barrientos, J. C., Kay, N. E., Reddy, N. M., Coutre, S. E., Tam, C. S. L., Mulligan, S. P., Jaeger, U., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1400376 · Cited by 1,665
Self-citationResistance Mechanisms for the Bruton's Tyrosine Kinase Inhibitor Ibrutinib
Woyach, J. A., Furman, R. R., Liu, T.-M., Ozer, H. G., Zapatka, M., Ruppert, A. S., Xue, L., Li, D. H.-H., Steggerda, S. M., Versele, M., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1400029 · Cited by 1,275
Self-citationDubovsky, J. A., Beckwith, K. A., Natarajan, G., Woyach, J. A., Jaglowski, S., Zhong, Y., Hessler, J. D., Liu, T.-M., Chang, B. Y., Larkin, K. M., et al. (2013) · Blood · doi:10.1182/blood-2013-06-507947 · Cited by 810
Self-citationHerman, S. E. M., Gordon, A. L., Hertlein, E., Ramanunni, A., Zhang, X., Jaglowski, S., Flynn, J., Jones, J., Blum, K. A., Buggy, J. J., et al. (2011) · Blood · doi:10.1182/blood-2011-01-328484 · Cited by 807
Self-citationPonader, S., Chen, S.-S., Buggy, J. J., Balakrishnan, K., Gandhi, V., Wierda, W. G., Keating, M. J., O'Brien, S., Chiorazzi, N., & Burger, J. A. (2012) · Blood · doi:10.1182/blood-2011-10-386417 · Cited by 640
Cited by
Sorted by citations
Items 201–300 of 585
Slonim, L. B., Ma, S., Behdad, A., & Chen, Q. (2020) · British Journal of Haematology · doi:10.1111/bjh.16948 · Cited by 32
Identification prognosis-associated immune genes in colon adenocarcinoma
Miao, Y., Wang, J., Ma, X., Yang, Y., & Mi, D. (2020) · Bioscience Reports · doi:10.1042/bsr20201734 · Cited by 32
Non-Covalent Bruton’s Tyrosine Kinase Inhibitors in the Treatment of Chronic Lymphocytic Leukemia
Montoya, S., & Thompson, M. C. (2023) · Cancers · doi:10.3390/cancers15143648 · Cited by 32
Management of Chronic Lymphocytic Leukemia in the Elderly
Barrientos, J. C. (2015) · Cancer Control · doi:10.1177/107327481502204s04 · Cited by 32
Prognostic and Predictive Molecular Biomarkers in Chronic Lymphocytic Leukemia
Lee, J., & Wang, Y. L. (2020) · Journal of Molecular Diagnostics · doi:10.1016/j.jmoldx.2020.06.004 · Cited by 34
Patel, V. M., Flanagan, C. E., Martins, M., Jones, C. L., Butler, R. M., Woollard, W. J., Bakr, F. S., Yoxall, A., Begum, N., Katan, M., et al. (2019) · Journal of Investigative Dermatology · doi:10.1016/j.jid.2019.07.693 · Cited by 32
Targeting BTK through microRNA in chronic lymphocytic leukemia
Bottoni, A., Rizzotto, L., Lai, T.-H., Liu, C., Smith, L. L., Mantel, R., Reiff, S. D., El‐Gamal, D., Larkin, K. T. M., Johnson, A. J., et al. (2016) · Blood · doi:10.1182/blood-2016-07-727750 · Cited by 31
Self-citationResisting the Resistance: Navigating BTK Mutations in Chronic Lymphocytic Leukemia (CLL)
Chirino, A., Montoya, S., Safronenka, A., & Taylor, J. (2023) · Genes · doi:10.3390/genes14122182 · Cited by 30
Schetelig, J., de Wreede, L. C., Andersen, N. S., Moreno, C., van Gelder, M., Vı́tek, A., Karas, M., Michallet, M., Machaczka, M., Gramatzki, M., et al. (2017) · British Journal of Haematology · doi:10.1111/bjh.14791 · Cited by 30
Tedeschi, A., Frustaci, A. M., Mauro, F. R., Chiarenza, A., Coscia, M., Ciolli, S., Reda, G., Laurenti, L., Varettoni, M., Murru, R., et al. (2021) · Blood Advances · doi:10.1182/bloodadvances.2021004824 · Cited by 30
The Evolving Landscape of Chronic Lymphocytic Leukemia on Diagnosis, Prognosis and Treatment
Carretero, C. P., González-Gascón-y-Marín, I., Rodríguez‐Vicente, A. E., Quijada‐Álamo, M., Hernández‐Rivas, J., Hernández‐Sánchez, M., & Hernández‐Rivas, J. M. (2021) · Diagnostics · doi:10.3390/diagnostics11050853 · Cited by 33
Mhibik, M., Gaglione, E. M., Eik, D., Kendall, E. K., Blackburn, A., Keyvanfar, K., Baptista, M. J., Ahn, I. E., Sun, C., Qi, J., et al. (2021) · Blood · doi:10.1182/blood.2020009686 · Cited by 30
Structure of BTK kinase domain with the second-generation inhibitors acalabrutinib and tirabrutinib
Lin, D. Y.-W., & Andreotti, A. H. (2023) · PLoS ONE · doi:10.1371/journal.pone.0290872 · Cited by 30
Lamothe, B., Wierda, W. G., Keating, M. J., & Gandhi, V. V. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-2522 · Cited by 31
Albitar, A., Ma, W., DeDios, I., Estella, J. J., Ahn, I. E., Farooqui, M. Z. H., Wiestner, A. U., & Albitar, M. X. (2017) · Oncotarget · doi:10.18632/oncotarget.15316 · Cited by 30
Mato, A. R., Nabhan, C., Kay, N. E., Lamanna, N., Kipps, T. J., Grinblatt, D. L., Flowers, C. R., Farber, C. M., Davids, M. S., Kiselev, P., et al. (2017) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2017.11.010 · Cited by 30
Tailored Treatment Strategies for Chronic Lymphocytic Leukemia in a Rapidly Changing Era
Brander, D. M., Islam, P., & Barrientos, J. C. (2019) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_238735 · Cited by 29
Ibrutinib in the treatment of chronic lymphocytic leukemia: 5 years on
Molica, S., Matutes, E., Tam, C. S. L., & Polliack, A. (2019) · Hematological Oncology · doi:10.1002/hon.2695 · Cited by 29
Eyre, T. A., Roeker, L. E., Fox, C. P., Gohil, S. H., Walewska, R. J., Walter, H. S., Forconi, F., Broom, A., Arumainathan, A. K., Brander, D. M., et al. (2019) · British Journal of Haematology · doi:10.1111/bjh.16271 · Cited by 29
Song, Y., Sun, M. Y., Qi, J., Xu, W., Zhou, J., Li, D., Li, J., Qiu, L., Du, C., Guo, H., et al. (2022) · British Journal of Haematology · doi:10.1111/bjh.18162 · Cited by 29
Stephens, D. M., Huang, Y., Ruppert, A. S., Walker, J. S., Canfield, D., Cempre, C. B., Fu, Q., Baker, S. D., Hu, B., Shah, H., et al. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-3867 · Cited by 29
Self-citationHing, Z. A., Walker, J. S., Whipp, E. C., Brinton, L. T., Cannon, M. J., Zhang, P., Sher, S., Cempre, C. B., Brown-Burke, F., Smith, P. L., et al. (2023) · Nature Communications · doi:10.1038/s41467-022-35778-1 · Cited by 30
Self-citationLampson, B. L., Kim, H. T., Davids, M. S., Abramson, J. S., Freedman, A. S., Jacobson, C. A., Armand, P. A., Joyce, R., Arnason, J. E., Rassenti, L. Z., et al. (2019) · Blood Advances · doi:10.1182/bloodadvances.2018030221 · Cited by 29
Tam, C. S. L., Balendran, S., & Blombery, P. A. (2025) · Blood · doi:10.1182/blood.2024026672 · Cited by 29
Front-line treatment of CLL in the era of novel agents
Robak, T., Stilgenbauer, S., & Tedeschi, A. (2016) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2016.12.007 · Cited by 28
Distinct immune signatures in chronic lymphocytic leukemia and Richter syndrome
Wang, Y., Sinha, S., Wellik, L. E., Secreto, C. R., Rech, K. L., Call, T. G., Parikh, S. A., Kenderian, S. S., Muchtar, E., Hayman, S. R., et al. (2021) · Blood Cancer Journal · doi:10.1038/s41408-021-00477-5 · Cited by 29
Prognostic Factors for Chronic Lymphocytic Leukemia
Chen, C., & Puvvada, S. D. (2016) · Current Hematologic Malignancy Reports · doi:10.1007/s11899-015-0294-x · Cited by 28
Larsen, J. T., Shanafelt, T. D., Leis, J. F., LaPlant, B. R., Call, T. G., Pettinger, A. M., Hanson, C. A., Erlichman, C., Habermann, T. M., Reeder, C. B., et al. (2017) · American Journal of Hematology · doi:10.1002/ajh.24762 · Cited by 28
Advances in the treatment of relapsed/refractory chronic lymphocytic leukemia
Shustik, C., Bence‐Bruckler, I., Delage, R., Owen, C., Toze, C. L., & Coutre, S. E. (2017) · Annals of Hematology · doi:10.1007/s00277-017-2982-1 · Cited by 28
Venetoclax Synergizes with Radiotherapy for Treatment of B-cell Lymphomas
O’Steen, S., Green, D. J., Gopal, A. K., Orozco, J. J., Kenoyer, A. L., Lin, Y., Wilbur, D. S., Hamlin, D. K., Fisher, D. R., Hylarides, M. D., et al. (2017) · Cancer Research · doi:10.1158/0008-5472.can-17-0082 · Cited by 27
Synergistic effect of ibrutinib and CD19 CAR‐T cells on Raji cells in vivo and in vitro
Liu, M., Wang, X., Li, Z., Zhang, R., Mu, J., Jiang, Y., Deng, Q., & Sun, L. (2020) · Cancer Science · doi:10.1111/cas.14638 · Cited by 27
Hampel, P. J., Cherng, H.-J. J., Call, T. G., Ding, W., Khanlari, M., McPhail, E. D., Miranda, R. N., Lin, P., Tawbi, H. A., Ferrajoli, A., et al. (2020) · Blood Advances · doi:10.1182/bloodadvances.2020002454 · Cited by 27
Mauro, F. R., Giannarelli, D., Visentin, A., Reda, G., Sportoletti, P., Frustaci, A. M., Chiarenza, A., Ciolli, S., Vitale, C., Laurenti, L., et al. (2021) · Cancers · doi:10.3390/cancers13133240 · Cited by 27
Innovative design and potential applications of covalent strategy in drug discovery
Tang, T., Luo, J., Zhang, D., Lü, Y., Liao, W., & Zhang, J. (2024) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2024.117202 · Cited by 27
Williams, A. M., Baran, A. M., Casulo, C., Reagan, P. M., Friedberg, J. W., Helber, M., Moore, J. E., Baloga, E., Zent, C. S., & Barr, P. M. (2018) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2018.10.005 · Cited by 26
Boudný, M., Zemanová, J., Khirsariya, P., Borský, M., Verner, J., Černá, J., Oltová, A., Šeda, V., Mráz, M., Jaroš, J., et al. (2019) · Haematologica · doi:10.3324/haematol.2018.203430 · Cited by 26
Allogeneic hematopoietic cell transplantation outcomes in patients with Richter’s transformation
Kim, H. T., Baker, P. O., Parry, E. M., Davids, M. S., Alyea, E. P., Ho, V. T., Cutler, C. S., Koreth, J., Gooptu, M., Romee, R., et al. (2021) · Haematologica · doi:10.3324/haematol.2021.279033 · Cited by 26
Flinn, I. W., Panayiotidis, P. G., Afanasyev, B. V., Janssens, A. M., Grosicki, S., Homenda, W., Smolej, L., Kuliczkowski, K., Doubek, M., Domnikova, N. P., et al. (2016) · American Journal of Hematology · doi:10.1002/ajh.24430 · Cited by 25
Danilov, A. V., & Persky, D. O. (2020) · British Journal of Haematology · doi:10.1111/bjh.17184 · Cited by 25
Unresolved questions in selection of therapies for treatment-naïve chronic lymphocytic leukemia
Bennett, R., Anderson, M. A., & Seymour, J. F. (2023) · Journal of Hematology & Oncology · doi:10.1186/s13045-023-01469-7 · Cited by 26
Allogeneic Hematopoietic Cell Transplantation for Richter Syndrome: A Single-Center Experience
Kharfan‐Dabaja, M. A., Kumar, A., Stingo, F. E., Khimani, F., Hussaini, M., Ayala, E., Nishihori, T., Shah, B. D., Locke, F. L., Pinilla-Ibarz, J. A., et al. (2017) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2017.10.002 · Cited by 26
The involvement of microRNA in the pathogenesis of Richter syndrome
Roosbroeck, K. V., Bayraktar, R., Calin, S., Bloehdorn, J., Dragomir, M. P., Okubo, K., Bertilaccio, M. T. S., Zupo, S., You, M. J., Gaïdano, G., et al. (2018) · Haematologica · doi:10.3324/haematol.2018.203828 · Cited by 24
BTK kinase activity is dispensable for the survival of diffuse large B-cell lymphoma
Yuan, H., Zhu, Y., Cheng, Y., Hou, J., Jin, F., Li, M., Jia, W. Q., Cheng, Z., Xing, H., Liu, M., et al. (2022) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2022.102555 · Cited by 24
Treatment Refractoriness in Chronic Lymphocytic Leukemia: Old and New Molecular Biomarkers
Maher, N., Mouhssine, S., Matti, B. F., Alwan, A., & Gaïdano, G. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241210374 · Cited by 26
Rossi, D., Gerber, B., & Stüssi, G. (2016) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2016.1250264 · Cited by 24
Guo, X., Yang, D., Fan, Z., Zhang, N., Zhao, B., Huang, C., Wang, F., Ma, R., Meng, M., & Deng, Y. (2019) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2019.06.035 · Cited by 24
Pepe, F., & Balatti, V. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9020593 · Cited by 24
Duvelisib for the treatment of chronic lymphocytic leukemia
Frustaci, A. M., Tedeschi, A., Deodato, M., Zamprogna, G., Cairoli, R., & Montillo, M. (2020) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2020.1751123 · Cited by 24
Aulakh, S., Reljic, T., Yassine, F., Ayala, E., Chávez, J. C., Chanan-Khan, A. A., Pinilla-Ibarz, J. A., Kumar, A., & Kharfan‐Dabaja, M. A. (2020) · Hematology/Oncology and Stem Cell Therapy · doi:10.1016/j.hemonc.2020.05.002 · Cited by 24
Arthur, R., Valle‐Argos, B., Steele, A. J., & Packham, G. (2020) · Exploration of Targeted Anti-tumor Therapy · doi:10.37349/etat.2020.00009 · Cited by 24
Koenig, K. L., Huang, Y., Dotson, E. K., Sheredy, S., Bhat, S. A., Byrd, J. C., Desmond, E., Ford, J., Iarocci, S., Jones, J. A., et al. (2020) · Blood Advances · doi:10.1182/bloodadvances.2020002593 · Cited by 24
Self-citationOptimizing frontline therapy of CLL based on clinical and biological factors
Fischer, K., & Hallek, M. J. (2017) · Hematology · doi:10.1182/asheducation-2017.1.338 · Cited by 23
Lenartova, A., Randen, U., Johannesen, T. B., & Tjønnfjord, G. E. (2019) · Cancer Epidemiology · doi:10.1016/j.canep.2019.04.002 · Cited by 23
Das, D., Wang, J., & Hong, J. (2022) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026622666220801101706 · Cited by 23
Voltan, R., Rimondi, E., Melloni, E., Rigolin, G. M., Casciano, F., Arcidiacono, M. V., Celeghini, C., Cuneo, A., Zauli, G., & Secchiero, P. (2016) · Oncotarget · doi:10.18632/oncotarget.12139 · Cited by 24
Byrd, J. C., Ruppert, A. S., Heerema, N. A., Halvorson, A. E., Hoke, E. E., Smith, M. R., Godwin, J. E., Couban, S., Fehniger, T. A., Thirman, M. J., et al. (2018) · Blood Advances · doi:10.1182/bloodadvances.2017015396 · Cited by 23
Self-citationCurrent Treatment of Refractory/Relapsed Chronic Lymphocytic Leukemia: A Focus on Novel Drugs
Smolewski, P., & Robak, T. (2020) · Acta Haematologica · doi:10.1159/000510768 · Cited by 23
Montserrat, E., & Dreger, P. (2016) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2016.02.013 · Cited by 24
Yazdy, M. S., Mato, A. R., & Cheson, B. D. (2018) · Blood · doi:10.1182/blood-2018-08-869503 · Cited by 23
The TKI Era in Chronic Leukemias
Novellis, D. D., Cacace, F., Caprioli, V., Wierda, W. G., Mahadeo, K. M., & Tambaro, F. P. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13122201 · Cited by 23
Kittai, A. S., Huang, Y., Beckwith, K. A., Bhat, S. A., Bond, D. A., Byrd, J. C., Goldstein, D. J., Grever, M. R., Miller, C. R., Rogers, K. A., et al. (2022) · American Journal of Hematology · doi:10.1002/ajh.26755 · Cited by 22
Self-citationYang, X., Zanardo, E., Lejeune, D., Nigris, E. D., Sarpong, E., Farooqui, M. Z. H., & Laliberté, F. (2024) · The Oncologist · doi:10.1093/oncolo/oyad324 · Cited by 22
Falchi, L., Baron, J. M., Orlikowski, C. A., & Ferrajoli, A. (2016) · Mediterranean Journal of Hematology and Infectious Diseases · doi:10.4084/mjhid.2016.011 · Cited by 21
Experience with ibrutinib for first-line use in patients with chronic lymphocytic leukemia
Itchaki, G., & Brown, J. R. (2017) · Therapeutic Advances in Hematology · doi:10.1177/2040620717741861 · Cited by 23
PLCG2 as a potential indicator of tumor microenvironment remodeling in soft tissue sarcoma
Li, Z., Zhao, R., Yang, W., Li, C., Huang, J., Wen, Z., Du, G., & Jiang, L. (2021) · Medicine · doi:10.1097/md.0000000000025008 · Cited by 21
Mauro, F. R., Scalzulli, P. R., Scarfò, L., Minoia, C., Murru, R., Sportoletti, P., Frigeri, F., Albano, F., Renzo, N. D., Sanna, A., et al. (2024) · Cancers · doi:10.3390/cancers16061228 · Cited by 21
Zerbit, J., Chevret, S., Bernard, S., Kroemer, M., Ablard, C., Harel, S., Brice, P., Madelaine, I., & Thiéblemont, C. (2020) · Annals of Hematology · doi:10.1007/s00277-020-04045-y · Cited by 21
Reining in BTK: Interdomain Interactions and Their Importance in the Regulatory Control of BTK
Kueffer, L. E., Joseph, R. E., & Andreotti, A. H. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.655489 · Cited by 22
Gustine, J. N., Sarosiek, S., Flynn, C. A., Meid, K., Leventoff, C. R., White, T., Guerrera, M. L., Xu, L., Kofides, A., Tsakmaklis, N., et al. (2021) · Haematologica · doi:10.3324/haematol.2021.279112 · Cited by 21
Woyach, J. A. (2015) · Hematology · doi:10.1182/asheducation-2015.1.355 · Cited by 20
Self-citationShadman, M. S., Manzoor, B. S., Sail, K., Tuncer, H. H., Allan, J. N., Ujjani, C. S., Emechebe, N. C., Kamalakar, R., Coombs, C. C., Leslie, L. A., et al. (2023) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2023.03.010 · Cited by 21
Woyach, J. A., Ghia, P., Byrd, J. C., Ahn, I. E., Moreno, C., O'Brien, S. M., Jones, D. M., Cheung, L. W. K., Chong, E. Y., Kwei, K. A., et al. (2023) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-22-3887 · Cited by 20
Self-citationMato, A. R., Samp, J. C., Gauthier, G., Terasawa, E., & Brander, D. M. (2018) · Cancer Biology & Therapy · doi:10.1080/15384047.2018.1449616 · Cited by 20
Gui, F., Jiang, J., He, Z., Li, L., Li, Y., Deng, Z., Lu, Y., Wu, X., Chen, G., Su, J., et al. (2019) · British Journal of Pharmacology · doi:10.1111/bph.14809 · Cited by 20
Transformation to plasmablastic lymphoma in CLL upon ibrutinib treatment
Marvyin, K., Tjønnfjord, E. B., Breland, U. M., & Tjønnfjord, G. E. (2020) · BMJ Case Reports · doi:10.1136/bcr-2020-235816 · Cited by 20
Bödör, C., Kotmayer, L., László, T., Takács, F., Barna, G., Kiss, R., Sebestyén, E., Nagy, T., Hegyi, L. L., Mikala, G., et al. (2021) · British Journal of Haematology · doi:10.1111/bjh.17502 · Cited by 20
BTK inhibitors resistance in B cell malignancies: Mechanisms and potential therapeutic strategies
Liu, X., Lin, Y., Zhuang, Q., Deng, H., Liu, A., & Sun, J. (2025) · Blood Reviews · doi:10.1016/j.blre.2025.101273 · Cited by 19
Managing Patients With TP53-Deficient Chronic Lymphocytic Leukemia
Edelmann, J., & Gribben, J. G. (2017) · Journal of Oncology Practice · doi:10.1200/jop.2017.023291 · Cited by 19
Resistance mechanism for ibrutinib in marginal zone lymphoma
Epperla, N., Shana’ah, A. Y., Jones, D. M., Christian, B. A., Ayyappan, S. R., Maddocks, K. J., & Woyach, J. A. (2019) · Blood Advances · doi:10.1182/bloodadvances.2018029058 · Cited by 19
Self-citationPotential of BCL2 as a target for chronic lymphocytic leukemia treatment
Moia, R., Diop, F., Favini, C., Kodipad, A. A., & Gaïdano, G. (2018) · Expert Review of Hematology · doi:10.1080/17474086.2018.1456332 · Cited by 19
Nuttall, E., Tung, J., Trounce, E., Johnston, R. E., & Chevassut, T. J. T. (2019) · Journal of Blood Medicine · doi:10.2147/jbm.s202286 · Cited by 19
Preclinical evaluation of the Hsp90 inhibitor SNX-5422 in ibrutinib resistant CLL
Chen, T. L., Harrington, B. K., Truxall, J., Wasmuth, R., Prouty, A., Sloan, S. L., Lehman, A. M., Sampath, D., Orlemans, E. O. M., Baiocchi, R. A., et al. (2021) · Journal of Hematology & Oncology · doi:10.1186/s13045-021-01039-9 · Cited by 19
Self-citationTargeting the p53 Pathway in CLL: State of the Art and Future Perspectives
Kwok, M., Agathanggelou, A., Davies, N., & Stanković, T. (2021) · Cancers · doi:10.3390/cancers13184681 · Cited by 20
Recent advances in therapy of chronic lymphocytic leukaemia
Routledge, D. J. M., & Bloor, A. J. C. (2016) · British Journal of Haematology · doi:10.1111/bjh.14184 · Cited by 18
Sequencing of chronic lymphocytic leukemia therapies
Barrientos, J. C. (2016) · Hematology · doi:10.1182/asheducation-2016.1.128 · Cited by 20
Harnessing p53 for targeted cancer therapy: new advances and future directions
Andrysík, Z., & Espinosa, J. M. (2025) · Transcription · doi:10.1080/21541264.2025.2452711 · Cited by 19
Davids, M. S., Vartanov, A. R., Werner, L. L., Neuberg, D. S., Cin, P. D., & Brown, J. R. (2015) · British Journal of Haematology · doi:10.1111/bjh.13498 · Cited by 18
Kabadi, S., Near, A. M., Wada, K., & Burudpakdee, C. (2019) · Cancer Medicine · doi:10.1002/cam4.2559 · Cited by 18
Mato, A. R., Sharman, J. P., Biondo, J. M. L., Wu, M., Mun, Y., Kim, S. Y., Humphrey, K., Boyer, M., Zhu, Q., & Seymour, J. F. (2020) · Haematologica · doi:10.3324/haematol.2020.266486 · Cited by 18
Hallek, M. J. (2023) · Hematological Oncology · doi:10.1002/hon.3145 · Cited by 19
Chiang, T., Wang, C., Lin, Y., You, J., Chen, J., & Chen, S. (2017) · Journal of Advanced Nursing · doi:10.1111/jan.13443 · Cited by 18
Narezkina, A., Akhter, N., Lu, X., Émond, B., Panjabi, S. S., Forbes, S. P., Hilts, A., Liu, S., Lafeuille, M., Lefèbvre, P., et al. (2022) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2022.07.004 · Cited by 17
A Review of Resistance Mechanisms to Bruton’s Kinase Inhibitors in Chronic Lymphocytic Leukemia
Wiśniewski, K., & Puła, B. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25105246 · Cited by 20
Ondrišová, L., Šeda, V., Hlavac, K., Petra, P., Hoferkova, E., Chiodin, G., Košťálová, L., Pavlasová, G. M., Filip, D., Večeřa, J., et al. (2024) · Journal of Clinical Investigation · doi:10.1172/jci173770 · Cited by 17
Agarwal, R., Dawson, M. A., Dreyling, M. H., & Tam, C. S. L. (2018) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2018.1457148 · Cited by 17
Walliser, C., Wist, M., Hermkes, E., Zhou, Y., Schade, A., Haas, J., Deinzer, J., Désiré, L., Li, S. S. C., Stilgenbauer, S., et al. (2018) · Oncotarget · doi:10.18632/oncotarget.26173 · Cited by 17
Immunochemotherapy for Richter syndrome: current insights
Puła, B., Salomon‐Perzyński, A., Prochorec‐Sobieszek, M., & Jamroziak, K. (2019) · ImmunoTargets and Therapy · doi:10.2147/itt.s167456 · Cited by 17
Resistance Mechanisms to Targeted Agents in Chronic Lymphocytic Leukemia
Kittai, A. S., & Woyach, J. A. (2019) · The Cancer Journal · doi:10.1097/ppo.0000000000000406 · Cited by 19
Self-citationDiamantopoulos, P. T., Kalopisis, K., Tsatsou, A., Efthymiou, A., Giannakopoulou, N., Chatzidavid, S., & Viniou, N. (2022) · European Journal Of Haematology · doi:10.1111/ejh.13751 · Cited by 17
Richter Syndrome in Chronic Lymphocytic Leukemia
Vitale, C., & Ferrajoli, A. (2016) · Current Hematologic Malignancy Reports · doi:10.1007/s11899-016-0300-y · Cited by 17
Metadata
- Authors
- Maddocks, K. J., Ruppert, A. S., Lozanski, G., Heerema, N. A., Zhao, W., Abruzzo, L., Lozanski, A., Davis, M., Gordon, A., Smith, L. L., Mantel, R., Jones, J. A., Flynn, J. M., Jaglowski, S. M., Andritsos, L. A., Awan, F., Blum, K. A., Grever, M. R., Johnson, A. J., Byrd, J. C., & Woyach, J. A.
- Affiliations
- The Ohio State University (US)
- Corresponding author
- Woyach, Jennifer A.
- ORCID
- Venue
- JAMA Oncology
- Publisher
- American Medical Association (AMA)
- Published
- 2015-04-01
- Volume
- 1
- Issue
- 1
- Pages
- 80
- ISSN
- 2374-2437 (ISSN-L)
- PMC
- PMC4520535
- OpenAlex
- W1999128869
- Cited by
- 584
- References
- 21
- Citations by year
- 2026: 13 · 2025: 29 · 2024: 35 · 2023: 38 · 2022: 47 · 2021: 59 · 2020: 65 · 2019: 72 · 2018: 60 · 2017: 85 · 2016: 64 · 2015: 16
- FWCI
- 41.98
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- JAMA Oncology (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Institutes of Health (4p01ca081534-16)
- National Cancer Institute (P01CA095426, U10CA180861, P50CA140158, R01CA183444, P01CA95426, K23CA178183, R01CA177292, P01-CA-081534)
- Topics
- Health Sciences › Medicine › Hematology › Chronic Lymphocytic Leukemia Research
- Health Sciences › Medicine › Pathology and Forensic Medicine › Lymphoma Diagnosis and Treatment
- Health Sciences › Medicine › Hematology › Acute Lymphoblastic Leukemia research
- Keywords
- chronic lymphocytic leukemia, BTK inhibitors, treatment discontinuation, Richter transformation, BTK mutations, PLCG2 mutations, relapse, deep sequencing, prognostic factors, sequential clinical trials, targeted therapy resistance
- MeSH terms
- Agammaglobulinaemia Tyrosine Kinase, Adenine, Adult, Aged, Aged, 80 and over, Clinical Trials as Topic, DNA Mutational Analysis, Female, Humans, Male, Middle Aged, Mutation, Ohio, Piperidines, Protein-Tyrosine Kinases, Pyrazoles, Pyrimidines, Recurrence, Risk Factors, Time Factors, Biomarkers, Tumor, Leukemia, Lymphocytic, Chronic, B-Cell, Treatment Outcome, Disease Progression, Protein Kinase Inhibitors, Phospholipase C gamma, Kaplan-Meier Estimate, Molecular Targeted Therapy, High-Throughput Nucleotide Sequencing
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
